ARA55 Inhibitors
Chemical inhibitors of ARA55 operate through various mechanisms to halt the functional activities of this protein. Bisindolylmaleimide targets protein kinase C, an important enzyme in the signaling pathways that influence ARA55 activity. By inhibiting PKC, Bisindolylmaleimide reduces the phosphorylation of ARA55, leading to the dampening of its function. Similarly, LY294002 inhibits phosphoinositide 3-kinases, which are upstream regulators of pathways that ARA55 is involved in. This inhibition results in a decreased activation of ARA55. U0126 takes a different approach by targeting MEK1/2, enzymes within the MAPK/ERK pathway, which ARA55 interacts with. Inhibition of MEK by U0126 suppresses the ERK-mediated phosphorylation of ARA55. SB203580 and SP600125 inhibit p38 MAPK and JNK, respectively, both of which are kinases that can regulate ARA55 through phosphorylation. Their inhibition leads to reduced phosphorylation and consequent decrease in ARA55 activity.
Furthermore, Gefitinib targets the EGFR tyrosine kinase, which upon activation can initiate several downstream pathways involving ARA55. By preventing EGFR phosphorylation, Gefitinib indirectly lowers the phosphorylation state of ARA55. Sorafenib, a multi-kinase inhibitor, affects the RAF/MEK/ERK pathway among others, which are associated with ARA55 activity. The inhibition by Sorafenib thus results in a reduction in ARA55 activity. Imatinib, which inhibits BCR-ABL tyrosine kinase, also influences the phosphorylation state of ARA55, leading to a decrease in its activity. Triciribine and Rapamycin act further downstream; Triciribine inhibits AKT, a kinase involved in ARA55-regulating pathways, while Rapamycin inhibits mTOR, a central regulator of cell growth and protein synthesis that affects ARA55 activity. WZ4003 and Sunitinib target NUAK kinases and multiple receptor tyrosine kinases, respectively, both influencing ARA55 phosphorylation and function. Through these varied but specific inhibitory actions, the chemical inhibitors collectively contribute to the modulation of ARA55 activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Inhibits protein kinase C (PKC), which is involved in the signaling pathways that lead to the activation of ARA55. By inhibiting PKC, this chemical would reduce the phosphorylation on ARA55, leading to its functional inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Inhibits phosphoinositide 3-kinases (PI3K), which are upstream regulators in pathways involving ARA55. By inhibiting PI3K, LY294002 can reduce the activation of downstream targets that would otherwise lead to the functional activation of ARA55. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
Inhibits MEK, which is part of the MAPK/ERK pathway. ARA55 has been found to interact with this pathway, and by inhibiting MEK, U0126 can suppress the ERK-mediated phosphorylation of ARA55, resulting in functional inhibition of ARA55. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
Inhibits p38 MAPK, which can influence pathways related to ARA55 activity. Through the inhibition of p38 MAPK, SB203580 can reduce the phosphorylation of ARA55, leading to a decrease in its functional activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, which is involved in signaling pathways that can phosphorylate and thereby regulate the activity of ARA55. SP600125 would reduce the phosphorylation of ARA55, thereby inhibiting its function. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase. Since EGFR can activate several downstream pathways that involve ARA55, inhibition by Gefitinib can lead to reduced phosphorylation and activation of ARA55. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Inhibits multiple kinases, including those involved in the RAF/MEK/ERK pathway, which can interact with ARA55. By inhibiting this pathway, Sorafenib can lead to decreased activation of ARA55. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Inhibits BCR-ABL tyrosine kinase and other kinases involved in the phosphorylation of proteins like ARA55. Imatinib thereby can lead to reduced phosphorylation and inhibition of ARA55's functional activity. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Inhibits AKT, which is involved in pathways that regulate the functional activity of ARA55. By inhibiting AKT, Triciribine would reduce the phosphorylation and subsequent activation of ARA55. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Inhibits mTOR, which is a key regulator of cell growth and protein synthesis, including the pathways involving ARA55. By inhibiting mTOR, Rapamycin can suppress the activity of pathways that lead to the activation of ARA55. | ||||||